Q1 Earnings Forecast for AURA Issued By Leerink Partnrs

Aura Biosciences, Inc. (NASDAQ:AURA) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Aura Biosciences in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings per share of ($0.49) for the quarter. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.47) EPS and Q4 2025 earnings at ($0.51) EPS.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02.

Several other equities research analysts have also commented on AURA. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. BTIG Research increased their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Scotiabank increased their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Finally, HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Aura Biosciences currently has an average rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $8.01 on Friday. The firm has a market cap of $400.10 million, a price-to-earnings ratio of -4.63 and a beta of 0.29. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38. The firm has a 50-day moving average price of $8.22 and a two-hundred day moving average price of $8.88.

Insider Buying and Selling at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now directly owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This represents a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,778 shares of company stock valued at $240,706 in the last three months. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

A number of large investors have recently added to or reduced their stakes in the business. Levin Capital Strategies L.P. raised its position in Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock worth $10,255,000 after purchasing an additional 783,984 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Aura Biosciences in the 4th quarter worth $87,000. JPMorgan Chase & Co. raised its position in Aura Biosciences by 107.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock worth $477,000 after purchasing an additional 27,718 shares during the period. Franklin Resources Inc. raised its position in Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock worth $15,571,000 after purchasing an additional 215,597 shares during the period. Finally, Barclays PLC raised its position in Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares during the period. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.